Lupin reçoit l'approbation de la Chine pour la suspension orale de phosphate d'oseltamivir

Lupin Limited has announced its entry into the Chinese market following the approval of its abbreviated new drug application for oseltamivir phosphate by the National Medical Products Administration of China. This launch is in partnership with Yabao Pharmaceuticals, a leading player in the Chinese pediatric pharmaceuticals market, marking a significant milestone in Lupin's global expansion.

The 6 mg/mL oral suspension of oseltamivir phosphate is set to be launched to enhance access, particularly for pediatric use. This move underscores Lupin's commitment to providing high-quality and affordable medications to patients and children in need worldwide.

The oral suspension of oseltamivir phosphate is indicated for the treatment of influenza A and B in patients aged two weeks and older, as well as for the prevention of influenza A and B in individuals aged one year and older.

Fabrice Egros, President of Business Development at Lupin, expressed enthusiasm over the approval, stating, "This is a strategic step into one of the largest pharmaceutical markets in the world, reflecting our shared commitment to expanding access to high-quality and affordable therapies, particularly in pediatric care. We look forward to enhancing our market presence through this partnership."

Wei Ren, President of Yabao, highlighted the significance of the approval, saying, "This marks a key milestone in our partnership with Lupin. It reinforces Yabao's commitment to quality pediatric medicines and demonstrates our close collaboration. We will continue to expand our R&D portfolio for chronic disease medications for pediatric and adult patients to further advance our operations together."